Phase II trial of definitive radiotherapy with leuprolide and enzalutamide in high-risk prostate cancer

被引：0
|
作者：
de la Calle, Claire Marie
Chang, Albert
Rashid, Ghezal
Wong, Anthony C.
Choi, Alice
Feng, Felix Y.
Gottschalk, Alexander R.
Menzel, Paul Lawrence
Carroll, Peter
Hao Gia Nguyen
机构：
[1] UCSF, San Francisco, CA USA
[2] Univ Calif San Francisco, San Francisco, CA 94143 USA
[3] Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA USA
[4] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA
[5] CPMC, San Francisco, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
323
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Addition of Enzalutamide to Leuprolide and Definitive Radiation Therapy Is Tolerable and Effective in High-Risk Localized or Regional Nonmetastatic Prostate Cancer: Results From a Phase 2 Trial
    Shee, Kevin
    de la Calle, Claire M.
    Chang, Albert J.
    Wong, Anthony C.
    Feng, Felix Y.
    Gottschalk, Alexander R.
    Carroll, Peter R.
    Nguyen, Hao G.
    ADVANCES IN RADIATION ONCOLOGY, 2022, 7 (05)
  • [2] EMBARK: A phase 3, randomized, efficacy and safety study of enzalutamide plus leuprolide, enzalutamide monotherapy and placebo plus leuprolide in men with high-risk nonmetastatic prostate cancer progressing after definitive therapy
    Miller, K.
    Mulders, P.
    Freedland, S. J.
    Scher, H.
    Shore, N.
    Park, E.
    Krivoshik, A.
    Phung, D.
    Modelska, K.
    Scardino, P.
    ANNALS OF ONCOLOGY, 2016, 27
  • [3] Results of a phase II trial of neoadjuvant abiraterone plus prednisone plus enzalutamide plus leuprolide (APEL) versus enzalutamide plus leuprolide (EL) for patients with high-risk localized prostate cancer (PC) undergoing radical prostatectomy (RP).
    McKay, Rana R.
    Xie, Wanling
    Lis, Rosina
    Ye, Huihui
    Zhang, Zhenwei
    Quoc-Dien Trinh
    Chang, Steven Lee
    Harshman, Lauren Christine
    Ross, Ashley
    Pienta, Kenneth J.
    Lin, Daniel W.
    Ellis, William J.
    Montgomery, Robert B.
    Chang, Peter
    Wagner, Andrew
    Bubley, Glenn
    Kibel, Adam S.
    Taplin, Mary-Ellen
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [4] Neoadjuvant Cabazitaxel plus Abiraterone/Leuprolide Acetate in Patients with High-Risk Prostate Cancer: ACDC-RP Phase II Trial
    Fleshner, Neil E.
    Sayyid, Rashid K.
    Hansen, Aaron R.
    Chin, Joseph L. K.
    Fernandes, Ricardo
    Winquist, Eric
    van der Kwast, Theodorus
    Sweet, Joan
    Lajkosz, Katherine
    Kenk, Miran
    Hersey, Karen
    Veloso, Rosette
    Berlin, Doron
    Herrera-Caceres, Jaime O.
    Sridhar, Srikala
    Moussa, Madeleine
    Finelli, Antonio
    Hamilton, Robert J.
    Kulkarni, Girish S.
    Zlotta, Alexandre R.
    Joshua, Anthony M.
    CLINICAL CANCER RESEARCH, 2023, 29 (19) : 3867 - 3874
  • [5] EMBARK: A PHASE 3 RANDOMIZED STUDY OF ENZALUTAMIDE ORPLACEBO PLUS LEUPROLIDE ACETATEANDENZALUTAMIDE MONOTHERAPY IN HIGH-RISK BIOCHEMICALLY RECURRENT PROSTATE CANCER
    Shore, Neal D.
    Luz, Murilo de Almeida
    De Giorgi, Ugo
    Gleave, Martin
    Gotto, Geoffrey T.
    Haas, Gabriel P.
    Ramirez-Backhaus, Miguel
    Rannikko, Antti
    Tarazi, Jamal
    Sridharan, Swetha
    Sugg, Jennifer
    Tang, Yiyun
    Tutrone, Ronald F.
    Venugopal, Balaji
    Villers, Arnauld
    Woo, Henry H.
    Zohren, Fabian
    Freedland, Stephen J.
    JOURNAL OF UROLOGY, 2023, 209 : E1190 - E1190
  • [6] A RANDOMIZED PHASE II TRIAL OF PROSTATE BOOST IRRADIATION WITH STEREOTACTIC BODY RADIOTHERAPY (SBRT) IN HIGH-RISK PROSTATE CANCER. THE PBS TRIAL
    Douvi, Georgia
    Isfahanian, Naghmeh
    Lukka, Himanshu
    IanDayes
    Quan, Kimmen
    Schnarr, Kara Lynne
    Goldberg, Mira
    Wright, Jim
    Hallock, Abhirami
    Ishkanian, Adrian
    Cuthbert, David
    Swaminath, Anand
    Chow, Tom
    Diamond, Kevin
    Cutz, Jean-Claude
    Kavsak, Peter
    Thabane, Lehana
    Tsakiridis, Theodoros
    RADIOTHERAPY AND ONCOLOGY, 2020, 150 : S87 - S88
  • [7] NEOADJUVANT ENZALUTAMIDE AND ANDROGEN DEPRIVATION IN HIGH-RISK PROSTATE CANCER: INITIAL IMAGING AND SURGICAL FINDINGS FROM A PHASE II CLINICAL TRIAL
    Gold, Samuel
    Marhamati, Sahwn
    Harmon, Stephanie
    Bloom, Jonathan
    Karzai, Fatima
    Hale, Graham
    Rayn, Kareem
    Sabarwal, Vik
    Mehralivand, Sherif
    Czarniecki, Marcin
    Smith, Clayton
    VanderWeele, David
    Dahut, William
    Turkbey, Baris
    Pinto, Peter
    JOURNAL OF UROLOGY, 2018, 199 (04): : E306 - E306
  • [8] Phase II Trial of Enzalutamide and Androgen Deprivation Therapy with Salvage Radiation in Men with High-risk Prostate-specific Antigen Recurrent Prostate Cancer: The STREAM Trial
    Bitting, Rhonda L.
    Healy, Patrick
    George, Daniel J.
    Anand, Monika
    Kim, Sung
    Mayer, Tina
    Winters, Carol
    Riggan, Colleen
    Rasmussen, Julia
    Wilder, Rhonda
    Stein, Mark
    Frizzell, Bart
    Harrison, Michael R.
    Zhang, Tian
    Lee, William R.
    Wu, Yuan
    Koontz, Bridget F.
    Armstrong, Andrew J.
    EUROPEAN UROLOGY ONCOLOGY, 2021, 4 (06): : 948 - 954
  • [9] Radiotherapy for high-risk prostate cancer
    Jahan J. Mohiuddin
    Brock R. Baker
    Ronald C. Chen
    Nature Reviews Urology, 2015, 12 : 145 - 154
  • [10] Radiotherapy for high-risk prostate cancer
    Mohiuddin, Jahan J.
    Baker, Brock R.
    Chen, Ronald C.
    NATURE REVIEWS UROLOGY, 2015, 12 (03) : 145 - 154
12345